Disease relevance of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid

• This indicates that magnesium lithospermate B helps to inhibit the progression of renal failure by scavenging radicals [1].
• The administration of magnesium lithospermate B in combination with captopril (2 mg/kg body weight, 2 times) caused a further increase in renal functional parameters, urinary sodium and creatinine excretions [2].
• Effect of magnesium lithospermate B in rats with sodium-induced hypertension and renal failure [3].
• Effect of magnesium lithospermate B on calcium and nitric oxide in endothelial cells upon hypoxia/reoxygenation [4].

High impact information on (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid

• A novel Na+ channel agonist, dimethyl lithospermate B, slows Na+ current inactivation and increases action potential duration in isolated rat ventricular myocytes [5].
• Extremely low bioavailability of magnesium lithospermate B, an active component from Salvia miltiorrhiza, in rat [6].
• Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by liquid chromatography/tandem mass spectrometry [7].
• Selective modulation of L-type calcium current by magnesium lithospermate B in guinea-pig ventricular myocytes [8].
• Peroxynitrite scavenging activity of lithospermate B from Salvia miltiorrhiza [9].

Chemical compound and disease context of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid

• Urinary excretion of prostaglandin E2 was increased by administration of magnesium lithospermate B, while those of 6-keto-prostaglandin F1 alpha and thromboxane B2 were unaffected at a dose of 5 mg or 10 mg/kg body weight/day for 12 or 24 days [10].
• These results suggest that the increased formation of PGE2 and 6-keto-PGF1 alpha might contribute to the improvement of adenine-induced renal failure in rats by magnesium lithospermate B [11].
• The increased levels of urea nitrogen in the blood of rats with induced renal failure were also lowered by administering magnesium lithospermate B [12].
• The levels of creatinine, methylguanidine and guanidino-succinic acid, which accumulate in the blood with the progress of renal failure, were decreased significantly in rats given magnesium lithospermate B [13].

Biological context of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid

• After intraperitoneal administration of magnesium lithospermate B to renal failure rats, the levels of glomerular filtration rate, renal plasma flow and renal blood flow were increased [11].
• In rats given magnesium lithospermate B at a dose of 5 mg/kg body weight/day for 12 or 24 days, glomerular filtration rate, renal plasma flow and renal blood flow were increased significantly [10].
• In rats given magnesium lithospermate B, blood pressure was significantly decreased, whereas urinary excretion of electrolytes was significantly increased [3].
• Pharmacokinetics of magnesium lithospermate B after intravenous administration in beagle dogs [14].
• Free radical scavenging and inhibition of lipid peroxidation by magnesium lithospermate B [15].

Anatomical context of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid

• Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line [16].
• Confirmation that magnesium lithospermate B ameliorates paraquat-induced injury in cultured renal epithelial cells [17].
• Magnesium lithospermate B inhibits hypoxia-induced calcium influx and nitric oxide release in endothelial cells [18].
• The effect of magnesium lithospermate B purified from Salviae Miltiorrhizae Radix on the kinin-prostaglandin E2 system was investigated using kidney slices and isolated kidney microsomes [19].

Associations of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid with other chemical compounds

• However, pretreatment with aprotinin abolished the renal function-facilitating action of magnesium lithospermate B concomitantly with a markedly increased urinary excretion of prostaglandin E2, 6-keto-prostaglandin F1 alpha and kallikrein [20].

Gene context of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid

• In contrast, rats given magnesium lithospermate B (10 mg/kg body weight) orally for 30 days after subtotal nephrectomy showed restoration of SOD and catalase activities to almost normal levels [1].
• The activity of kallikrein in urine increased markedly and significantly in rats given 5 or 10 mg of magnesium lithospermate B for 12 or 24 days [10].

Analytical, diagnostic and therapeutic context of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid

• Magnesium lithospermate B suppresses the increase of active oxygen in rats after subtotal nephrectomy [1].
• These results indicate that magnesium lithospermate B, a component of an Oriental medicine has potential as a new therapeutic agent for inhibiting the progression of renal dysfunction [13].

References